Sangamo showcases progress in our pre-clinical programs at ESGCT.
Click here to view
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Expanded Access Policy
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Expanded Access Policy
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
ESGCT 2023
Epigenetic Regulation for Neurology
Cell Therapy - Regulatory T-Cells (CAR-Tregs)
CAR-T in Oncology
Epigenetic Regulation for Neurology
ESGCT 2023
Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency
ESGCT 2023
Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF-As) as a Therapeutic Approach for Phelan-McDermid Syndrome
Cell Therapy - Regulatory T-Cells (CAR-Tregs)
ESGCT 2023
Myelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs – A novel approach to treat multiple sclerosis
ESGCT 2023
Evaluation of IL23R as a target for CAR-Tregs at the site of inflammation in subjects with Crohn’s Disease
ESGCT 2023
Multimerization of Chimeric Antigen Receptor (CAR) binding domains: A solution to assess tissue specificity of low to medium affinity scFv
CAR-T in Oncology
ESGCT 2023
Multiplex targeting of immune checkpoints with compact zinc finger repressors to improve anti-tumor activity of T cells